Serum lipid profile in psoriatic patients: Correlation between vascular adhesion protein 1 and lipoprotein (a)

Cell Biochemistry and Function

Volumn 31, Issue 1, 2013, Pages 36-40

  Nemati, Houshang ^a,b   Khodarahmi, Reza ^a,b   Rahmani, Ameneh ^b   Ebrahimi, Ali ^c   Amani, Mojtaba ^d   Eftekhari, Kamran ^b  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apolipoproteins; Lipids; Lp(a); Psoriasis; VAP 1

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VASCULAR ADHESION PROTEIN 1; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS;

ADULT; AMINE OXIDASE (COPPER-CONTAINING); APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS; MALE; MIDDLE AGED; PREVALENCE; PSORIASIS; THROMBOPHILIA; TRIGLYCERIDES;

EID: 84872383168     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2857     Document Type: Article

References (48)

1. Griffiths CEM, Voorhees JJ. Immunological mechanism involved in psoriasis. Semin Immunopathol 1992; 13: 441-444.
2. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
3. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
4. Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002; 169: 983-992.
5. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinant of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-708.
6. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54: 685-704.
7. Griffiths CE, Barker JNW. Pathogensis and clinical features of psoriasis. Lancet 2007; 360: 263-271.
8. Friedewald VE, Cather JC, Gelfand JM, et al. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008; 102: 1631-1643.
9. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007; 25: 529-534.
10. Gottieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21.
11. Pietrzak A, Lecewicz-Torun B. Activity of serum lipase [EC 3.1.1.3] and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002; 8: CR9-CR13.
12. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007; 2007: 78454.
13. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303(1-2): 33-39.
14. Kural BV, Örem A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82.
15. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.
16. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-II10.
17. Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 2007; 21(6): 802-805.
18. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
19. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270(2): 147-157.
20. Jaakkola K, Nikula T, Holopainen R, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 2000; 157: 463-471.
21. Dratelin CR, Martinez-Abundis E, Balcázar-Muñoz BR, Bustos-Saldaña R, González-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-885.
22. Fortinskaia ES, Torkhovskaia TI, Sharapova GI, Loginova TK, Kliuchnikova ZI, Khalilov EM. Features of distribution of free and esterified cholesterol in the epidermis, biological membranes and plasma lipoproteins in psoriasis. Klin Lab Diagn 1996; 4: 38-43.
23. Steinbrecher UP. Receptors for oxidized low density lipoprotein. Biochim Biophys Acta 1999; 1436(3): 279-298.
24. Walldius G, Jungner I. The apo B/apo A-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid - lowering therapy a review of the evidence. J Intern Med 2006; 259: 493-519.
25. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology 2008; 47: 718-723.
26. Vanizor Kural B, Orem A, Çimsit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332(1-2): 23-30.
27. Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44(1): 24-26.
28. Seckin D, Tokgozoglu L, Akkaya S. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 1994; 31(3 Pt 1): 445-449.
29. Seishima M, Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994; 130(6): 738-742.
30. Aysun Toker A, Kadi M, Yildirim K, Aksoy H, Akc F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009; 27: 176-180.
31. Pietrzak A, Kadzielewski J, Janowski K, et al. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int J Dermatol 2009; 48(4): 379-387.
32. Uyanik BS, Ari Z, Onur E, Gündüz K, Tanülkü S, Durkan K. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002 Jan; 40(1): 65-68.
33. Suleyman P, Figen G, Galip E, Mustafa S. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44(1): 24-26.
34. Leren TP, Maartmann-Moe K, Thune P, Berg K. Low density lipoprotein receptors in cultured skin fibroblasts from psoriasis patients. Clin Genet 1984; 25(3): 230-241.
35. Assous N, Touzé E, Meune C, Kahan A, Allanore Y. Morbimortlité cardiovasculaire au cours de la polyarthrite rhumatoïde: étude de cohorte hospitalière monocentrique française. Rev Rhum 2007; 74: 72-78.
36. García-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis. J Rheumatol 2009; 36: 1365-1370.
37. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 1986; 256: 2835-2838.
38. Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2008; 2: 267-273.
39. Nurmohamed MT. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag 2007; 3: 845-852.
40. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992; 257: 1407-1409.
41. Martelius T, Salaspuro V, Salmi M, et al. Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection. Am J Pathol 2004; 165: 1993-2001.
42. Arvilommi A-M, Salmi M, Kalimo K, Jalkanen S. Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1). Eur J Immunol 1996; 26: 825-833.
43. Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 1993; 178: 2255-2260.
44. Kurkijarvi R, Adams DH, Leino R, et al. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998; 161: 1549-1557.
45. Hisashi W, Masahiro T. E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques. Arch Dermatol 1994; 130: 457-463.
46. Madej A, Reich A, Orda A, Szepietowski JC. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol 2007; 21(1): 72-78.
47. Bonifati C, Trento E, Carducci M, et al. Soluble E-selectin and soluble tumour necrosis factor (60kD:) serum levels in patients with psoriasis. Dermatology 1995; 190: 128-131.
48. Carducci M, Mussi A, Bonifati C, et al. Correlation of lesional skin corneometry values with serum E-selectin levels and disease severity in patients affected by plaque-type psoriasis: recovery after effective therapy. J Dermatol 1995; 22: 475-479.